| |
| |
|
| Insider
Information: |
Ho Tony W |
| Relationship: |
Executive VP, Head of ... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
52,364 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,907,773 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
52,364 |
|
|
| Total
Value |
$2,907,773 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Crispr Therapeutics Ag |
CRSP |
Executive VP, Head of ... |
2021-12-06 |
52,364 |
2018-08-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-12-06 |
4 |
D |
$69.17 |
$872,026 |
D/D |
(12,607) |
52,364 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,667 |
64,971 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-03-10 |
4 |
D |
$124.15 |
$265,805 |
D/D |
(2,141) |
38,304 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,583 |
40,445 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-03-05 |
4 |
D |
$114.65 |
$181,720 |
D/D |
(1,585) |
35,862 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2021-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
37,447 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-12-21 |
4 |
AS |
$147.05 |
$3,514,610 |
D/D |
(23,551) |
33,964 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-12-21 |
4 |
OE |
$16.90 |
$398,012 |
D/D |
23,551 |
57,515 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-06-23 |
4 |
AS |
$75.20 |
$521,061 |
D/D |
(6,929) |
33,747 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-06-22 |
4 |
AS |
$70.14 |
$16,062 |
D/D |
(229) |
40,676 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-05-26 |
4 |
AS |
$70.14 |
$427,854 |
D/D |
(6,100) |
40,905 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-05-22 |
4 |
AS |
$70.05 |
$42,030 |
D/D |
(600) |
47,005 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-03-06 |
4 |
D |
$52.64 |
$82,276 |
D/D |
(1,563) |
47,605 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
49,168 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2019-08-02 |
4 |
D |
$52.56 |
$763,907 |
D/D |
(14,534) |
45,835 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Executive VP, Head of R&D |
• – – |
2019-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
60,369 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
See Remarks |
• – – |
2019-03-05 |
4 |
A |
$40.87 |
$408,700 |
D/D |
10,000 |
32,869 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
See Remarks |
• – – |
2018-08-02 |
4 |
D |
$48.43 |
$708,579 |
D/D |
(14,631) |
22,869 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
See Remarks |
• – – |
2018-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
0 |
- |
|
19 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
